Cancer drug-resistance and a look at specific proteins: Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and HSP70/90 organizing protein in proteomics clinical application

Journal of Proteome Research

Volumn 10, Issue 2, 2011, Pages 404-415

  Skalnikova, Helena ^a   Martinkova, Jirina ^a   Hrabakova, Rita ^a   Halada, Petr ^b   Dziechciarkova, Marta ^c   Hajduch, Marian ^c   Gadher, Suresh Jivan ^d   Hammar, Andreas ^e   Enetoft, Daniel ^e   Ekefjard, Andreas ^e   Forsstrom Olsson, Ola ^e   Kovarova, Hana ^a  

^a INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d Millipore Bioscience   (United States)

^e Ludesi AB   (Sweden)

Author keywords

Anti cancer drugs; Biomarker; Cancer; CDK inhibitor; CEM T lymphoblastic leukemia; Drug resistance; Hsp70 90 organizing protein; Proteomics; Rho GDP dissociation inhibitor 2; Y box binding protein 1

Indexed keywords

BOHEMINE; CELL PROTEIN; DAUNORUBICIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; RHO GDP BINDING PROTEIN; RHO GDP DISSOCIATION INHIBITOR 2; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; Y BOX BINDING PROTEIN 1;

ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL FRACTIONATION; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEOMICS; T CELL LEUKEMIA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTATIONAL BIOLOGY; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PROTEIN INTERACTION MAPPING; PROTEOME; PURINES; SPECTROPHOTOMETRY, ULTRAVIOLET; SUBCELLULAR FRACTIONS; TUMOR SUPPRESSOR PROTEINS; Y-BOX-BINDING PROTEIN 1;

EID: 79955393326     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100468w     Document Type: Article

References (39)

1. Raguz, S.; Yague, E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br. J. Cancer 2008, 99 (3), 387-91.
2. Zhang, J. T.; Liu, Y. Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat. Rev. 2007, 33 (8), 741-56. (Pubitemid 350082667)
3. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5 (4), 275-84. (Pubitemid 40488633)
4. Hajduch, M., Skalnikova, H., Halada, P., Vydra, D., Dzubak, P., Dziechciarkova, M., Strnad, M., Radioch, D., Kovarova, H., Cyclin-dependent kinase inhibitors and cancer: usefulness of proteomic approaches in assessment of the molecular mechanisms and efficacy of novel therapeutics. In Clinical Proteomics: From Diagnosis to Therapy; Van Eyk, J. E., Dunn, M. J., Eds.; Wiley-VCH: Weinheim, 2007; pp 177-202.
5. Kovarova, H.; Hajduch, M.; Korinkova, G.; Halada, P.; Krupickova, S.; Gouldsworthy, A.; Zhelev, N.; Strnad, M. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Electrophoresis 2000, 21 (17), 3757-64.
6. Dobashi, Y.; Takehana, T.; Ooi, A. Perspectives on cancer therapy: cell cycle blockers and perturbators. Curr. Med. Chem. 2003, 10 (23), 2549-58. (Pubitemid 37456025)
7. Noskova, V.; Dzubak, P.; Kuzmina, G.; Ludkova, A.; Stehlik, D.; Trojanec, R.; Janostakova, A.; Korinkova, G.; Mihal, V.; Hajduch, M. In vitro chemoresistance profile and expression/function of MDR associated proteins in resistant cell lines derived from CCRF- CEM, K562, A549 and MDA MB 231 parental cells. Neoplasma 2002, 49 (6), 418-25. (Pubitemid 36139245)
8. Towbin, H.; Staehelin, T.; Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 1979, 76 (9), 4350-4. (Pubitemid 9256559)
9. Skalnikova, H.; Halada, P.; Dzubak, P.; Hajduch, M.; Kovarova, H. Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identification of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry. Technol. Cancer Res. Treat. 2005, 4 (4), 447-54. (Pubitemid 41242617)
10. Linke, T.; Ross, A. C.; Harrison, E. H. Proteomic analysis of rat plasma by two-dimensional liquid chromatography and matrixassisted laser desorption ionization time-of-flight mass spectrometry. J. Chromatogr., A 2006, 1123 (2), 160-9. (Pubitemid 44137357)
11. Bader, A. G. YB-1 activities in oncogenesis: transcription and translation. Curr. Cancer Ther. Rev. 2006, 2 (1), 31-9. (Pubitemid 44082902)
12. Sorokin, A. V.; Selyutina, A. A.; Skabkin, M. A.; Guryanov, S. G.; Nazimov, I. V.; Richard, C.; Th'ng, J.; Yau, J.; Sorensen, P. H.; Ovchinnikov, L. P.; Evdokimova, V. Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J. 2005, 24 (20), 3602-12. (Pubitemid 41509367)
13. Honore, B.; Leffers, H.; Madsen, P.; Rasmussen, H. H.; Vandekerckhove, J.; Celis, J. E. Molecular cloning and expression of a transformation-sensitive human protein containing the TPR motif and sharing identity to the stress-inducible yeast protein STI1. J. Biol. Chem. 1992, 267 (12), 8485-91.
14. Longshaw, V. M.; Chapple, J. P.; Balda, M. S.; Cheetham, M. E.; Blatch, G. L. Nuclear translocation of the Hsp70/Hsp90 organizing protein mSTI1 is regulated by cell cycle kinases. J. Cell Sci. 2004, 117 (Pt. 5), 701-10. (Pubitemid 38263215)
15. Odunuga, O. O.; Longshaw, V. M.; Blatch, G. L. Hop: more than an Hsp70/Hsp90 adaptor protein. BioEssays 2004, 26 (10), 1058-68. (Pubitemid 39424809)
16. Petrak, J.; Toman, O.; Simonova, T.; Halada, P.; Cmejla, R.; Klener, P.; Zivny, J. Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts. Proteomics 2009, 9 (22), 5006-15.
17. Petrak, J.; Ivanek, R.; Toman, O.; Cmejla, R.; Cmejlova, J.; Vyoral, D.; Zivny, J.; Vulpe, C. D. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008, 8 (9), 1744-9. (Pubitemid 351678270)
18. Park, D. J.; Nakamura, H.; Chumakov, A. M.; Said, J. W.; Miller, C. W.; Chen, D. L.; Koeffler, H. P. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 1994, 9 (7), 1899-906. (Pubitemid 24194156)
19. Gildea, J. J.; Seraj, M. J.; Oxford, G.; Harding, M. A.; Hampton, G. M.; Moskaluk, C. A.; Frierson, H. F.; Conaway, M. R.; Theodorescu, D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002, 62 (22), 6418-23. (Pubitemid 35364098)
20. Seraj, M. J.; Harding, M. A.; Gildea, J. J.; Welch, D. R.; Theodorescu, D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin. Exp. Metastasis 2000, 18 (6), 519-25. (Pubitemid 32844253)
21. Theodorescu, D.; Sapinoso, L. M.; Conaway, M. R.; Oxford, G.; Hampton, G. M.; Frierson, H. F., Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin. Cancer Res. 2004, 10 (11), 3800-6. (Pubitemid 38697615)
22. Tapper, J.; Kettunen, E.; El-Rifai, W.; Seppala, M.; Andersson, L. C.; Knuutila, S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet. 2001, 128 (1), 1-6. (Pubitemid 32655473)
23. Jiang, W. G.; Watkins, G.; Lane, J.; Cunnick, G. H.; Douglas-Jones, A.; Mokbel, K.; Mansel, R. E. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin. Cancer Res. 2003, 9 (17), 6432-40. (Pubitemid 38031830)
24. Schunke, D.; Span, P.; Ronneburg, H.; Dittmer, A.; Vetter, M.; Holzhausen, H. J.; Kantelhardt, E.; Krenkel, S.; Muller, V.; Sweep, F. C.; Thomssen, C.; Dittmer, J. Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer Res. 2007, 67 (22), 10694-702. (Pubitemid 350145895)
25. Cho, H. J.; Baek, K. E.; Park, S. M.; Kim, I. K.; Choi, Y. L.; Nam, I. K.; Hwang, E. M.; Park, J. Y.; Han, J. Y.; Kang, S. S.; Kim, D. C.; Lee, W. S.; Lee, M. N.; Oh, G. T.; Kim, J. W.; Lee, C. W.; Yoo, J. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer. Clin. Cancer Res. 2009, 15 (8), 2612-9.
26. Zhao, J.; Chang, A. C.; Li, C.; Shedden, K. A.; Thomas, D. G.; Misek, D. E.; Manoharan, A. P.; Giordano, T. J.; Beer, D. G.; Lubman, D. M. Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping. Mol. Cell. Proteomics 2007, 6 (6), 987-99. (Pubitemid 47019400)
27. Goto, T.; Takano, M.; Sakamoto, M.; Kondo, A.; Hirata, J.; Kita, T.; Tsuda, H.; Tenjin, Y.; Kikuchi, Y. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol. Rep. 2006, 15 (5), 1265-71.
28. Sinha, P.; Hutter, G.; Kottgen, E.; Dietel, M.; Schadendorf, D.; Lage, H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 1999, 20 (14), 2961-9. (Pubitemid 29517228)
29. Kuwano, M.; Oda, Y.; Izumi, H.; Yang, S. J.; Uchiumi, T.; Iwamoto, Y.; Toi, M.; Fujii, T.; Yamana, H.; Kinoshita, H.; Kamura, T.; Tsuneyoshi, M.; Yasumoto, K.; Kohno, K. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol. Cancer Ther. 2004, 3 (11), 1485-92. (Pubitemid 39562593)
30. Sutherland, B. W.; Kucab, J.; Wu, J.; Lee, C.; Cheang, M. C.; Yorida, E.; Turbin, D.; Dedhar, S.; Nelson, C.; Pollak, M.; Leighton Grimes, H.; Miller, K.; Badve, S.; Huntsman, D.; Blake-Gilks, C.; Chen, M.; Pallen, C. J.; Dunn, S. E. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005, 24 (26), 4281-92. (Pubitemid 40961781)
31. Tanji, H.; Ishikawa, C.; Sawada, S.; Nakachi, S.; Takamatsu, R.; Matsuda, T.; Okudaira, T.; Uchihara, J. N.; Ohshiro, K.; Tanaka, Y.; Senba, M.; Uezato, H.; Ohshima, K.; Duc Dodon, M.; Wu, K. J.; Mori, N. Aberrant expression of the transcription factor Twist in adult T-cell leukemia. Blood 2010, 116 (8), 1386.
32. Bargou, R. C.; Jurchott, K.; Wagener, C.; Bergmann, S.; Metzner, S.; Bommert, K.; Mapara, M. Y.; Winzer, K. J.; Dietel, M.; Dorken, B.; Royer, H. D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 1997, 3 (4), 447-50. (Pubitemid 27145688)
33. Fujita, T.; Ito, K.; Izumi, H.; Kimura, M.; Sano, M.; Nakagomi, H.; Maeno, K.; Hama, Y.; Shingu, K.; Tsuchiya, S.; Kohno, K.; Fujimori, M. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin. Cancer Res. 2005, 11 (24 Pt. 1), 8837-44. (Pubitemid 43005936)
34. Oda, Y.; Ohishi, Y.; Saito, T.; Hinoshita, E.; Uchiumi, T.; Kinukawa, N.; Iwamoto, Y.; Kohno, K.; Kuwano, M.; Tsuneyoshi, M. Nuclear expression of Y-box-binding protein-1 correlates with P-glycopro- tein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J. Pathol. 2003, 199 (2), 251-8. (Pubitemid 36176032)
35. Zhu, K.; Zhao, J.; Lubman, D. M.; Miller, F. R.; Barder, T. J. Protein pI shifts due to posttranslational modifications in the separation and characterization of proteins. Anal. Chem. 2005, 77 (9), 2745-55. (Pubitemid 40617320)
36. Lassle, M.; Blatch, G. L.; Kundra, V.; Takatori, T.; Zetter, B. R. Stress-inducible, murine protein mSTI1. Characterization of binding domains for heat shock proteins and in vitro phosphorylation by different kinases. J. Biol. Chem. 1997, 272 (3), 1876-84. (Pubitemid 27043280)
37. Daniel, S., Soti, C., Csermely, P., Bradley, G., Blatch, G. L. Hop: An Hsp70/Hsp90 co-chaperone that functions within and beyond Hsp70/Hsp90 protein folding pathways. In Networking of Chaperones by Co-Chaperones; Blatch, G. L., Ed.; Springer: New York, 2007; pp 26-37.
38. Daniel, S.; Bradley, G.; Longshaw, V. M.; Soti, C.; Csermely, P.; Blatch, G. L. Nuclear translocation of the phosphoprotein Hop (Hsp70/Hsp90 organizing protein) occurs under heat shock, and its proposed nuclear localization signal is involved in Hsp90 binding. Biochim. Biophys. Acta 2008, 1783 (6), 1003-14.
39. Cappellini, A.; Chiarini, F.; Ognibene, A.; McCubrey, J. A.; Martelli, A. M. The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers. Cell Cycle 2009, 8 (9), 1421-5.